On April 2, 2026, CMS issued the Contract Year 2027 Medicare Advantage and Part D final rule. It is part of a multi-year reshaping of the Star Ratings program that began with the 2020 and 2024 rulemakings. The headline framing is "simpler." For a quality leader, the practical reality is "less room for error." Below are the verified, dated changes that matter, and what to do about each.

Tukey outlier deletion is in effect and it lifted the bar

Tukey outlier deletion removes statistical outliers, frequently a handful of very low performers, before CMS sets cut points for non-CAHPS measures. It was finalized in 2020 rulemaking and has applied since the 2024 Star Ratings, per the CMS Star Ratings technical notes. The effect is mechanical: when low-end outliers no longer drag the distribution down, cut points rise, and the score needed to reach 4 stars on a given measure climbs.

This is not a future risk. It already happened. If your internal targets were set against pre-Tukey cut points, they are stale.

Guardrails are largely removed, so cut points move more

Guardrails capped how far a measure's cut point could move year over year, which dampened the full effect of Tukey and of real shifts in the field. With guardrails removed for most measures, cut points can move more freely from one year to the next. The result is volatility: a level of performance that earned 4 stars last year can earn 3 stars this year if competitors improved or if Tukey pushed the threshold up.

Hitting last year's cut point is no longer a plan. The target moves, and now it can move further.

The health equity reward was reversed, not added

This is the change most likely to be misremembered, so be precise. The 2024 final rule finalized a Health Equity Index reward, later renamed the Excellent Health Outcomes for All reward, to begin with the 2027 Star Ratings. It was designed to reward plans for outcomes among enrollees with social risk factors and to replace the existing reward factor.

In the Contract Year 2027 final rule, CMS finalized its decision not to implement that reward and to continue the historical reward factor instead, the one the equity reward was set to replace. So the net change for the 2027 Star Ratings is a reversal back to the existing reward factor, while CMS works to simplify the methodology. If your 2027 forecast assumed an equity-based reward was coming, remove it.

The measure set is shrinking, which concentrates weight

For the 2027 Star Ratings, CMS removes three measures and adds three. The removed measures are Care for Older Adults Pain Assessment, Medication Reconciliation Post-Discharge, and MTM Program Completion Rate for CMR (the MTM measure will return as a new measure with the 2029 Star Ratings, measurement year 2027). The added measures are Care for Older Adults Functional Status Assessment, Concurrent Use of Opioids and Benzodiazepines, and Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults. All three added measures are process measures at weight 1. Colorectal Cancer Screening is also being respecified and treated as a new measure.

Fewer measures sounds like relief. It is the opposite. Removing measures concentrates the program's total weight onto the measures that remain. The heaviest carry sits with Health Plan Quality Improvement and Drug Plan Quality Improvement at weight 5; the three Part D adherence measures, Plan All-Cause Readmissions, Diabetes Care Blood Sugar Controlled, Controlling Blood Pressure, and the two Improving or Maintaining Physical and Mental Health measures at weight 3; and patient-experience, complaints, and access measures at weight 2. Surviving measures matter more than they did before.

Part D adherence weighting is temporarily reduced, then expected to return

The three Part D medication-adherence measures, covering diabetes medications, hypertension RAS antagonists, and cholesterol statins, are normally triple-weighted. For measurement year 2026, which feeds the 2028 Star Ratings, they are temporarily single-weighted while CMS phases in sociodemographic status (SDS) risk adjustment for these measures. They are expected to return to triple-weighting for measurement year 2027, which feeds the 2029 Star Ratings.

Do not read the temporary single-weighting as a reason to ease off adherence. The clinical work, and the member outreach behind it, takes months to move. Building adherence capacity in the single-weight year is exactly how you are ready when the triple weight returns. We break down the underlying mechanics in our PDC math guide.

What the changes add up to

2024
Star Ratings year Tukey outlier deletion took effect, raising cut points
Apr 2, 2026
CY2027 final rule reversing the equity reward back to the historical reward factor
1x → 3x
Part D adherence weight: single for MY2026, expected back to triple for MY2027

Taken together: harder cut points, more volatility, fewer measures carrying more weight each, and a reward methodology that snapped back to where it was. For a plan sitting near a star boundary, a small miss on a high-weight measure now has outsized financial consequences.

The financial mechanism is worth restating, because it is why this is a leadership problem and not just a quality-department problem. In Medicare Advantage, reaching the 4-star threshold earns a quality bonus payment that flows into plan revenue and rebate dollars, and the difference between 3.5 and 4 stars at the contract level is measured in many millions of dollars. When cut points rise and stop being capped by guardrails, the same clinical performance that cleared the bar last year can fall short this year. The exposure did not change because your members got sicker. It changed because the scoring did.

Why volatility is the hard part

A static target can be planned against. A moving one cannot, at least not with a year-end push. If the cut point for a measure can jump several points in either direction, the only safe posture is to perform well clear of the boundary, all year, on every measure that carries weight. That is a different operating model than the historical pattern of sprinting in the fourth quarter to clear known thresholds. The plans that struggle most under the new methodology are the ones still managing to last year's numbers.

What quality leaders should do now

  1. Re-forecast without guardrails. Rebuild your projections using post-Tukey, no-guardrail cut-point assumptions, not last year's thresholds. Identify every measure where your contract sits within a few points of a star boundary.
  2. Triage by weight and proximity. Concentrated weight means a 4-weighted outcome measure one point under the cut is worth more attention than three comfortably-passing low-weight measures. Sequence the work accordingly.
  3. Shift to year-round execution. Volatile cut points punish the year-end scramble. The measures move with continuous member contact: gap closure, adherence, follow-up after acute events. Build the operating cadence that runs all year.
  4. Hold adherence steady through the single-weight year. Treat measurement year 2026 as the build year so the team is ready when triple weighting returns for measurement year 2027.
  5. Verify every weight against current technical notes. Weights and the measure set are moving year to year. Confirm against the CMS technical notes for your specific measurement year before locking a plan.

This is where execution beats analytics. A dashboard can show you the boundary measures; it cannot make the calls, book the visits, and document the closures that move them. Across Pelica deployments, year-round execution has improved gap closure by 41% and tripled outreach capacity per coordinator with no new headcount.

Sources and further reading